Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

45.91 +0.22 (+0.47%)

Streaming Delayed Price Updated: 3:26 PM EDT, Aug 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

42 43 Next >

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? ↗

October 31, 2024

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.

Via Benzinga

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗

October 28, 2024

One of these players has split its stock in the past. The other one hasn't.

Via The Motley Fool

Why Sanofi Stock Flew Higher on Friday ↗

October 25, 2024

No investor can ignore a crushing bottom-line beat and raised profitability guidance.

Via The Motley Fool

Sanofi (SNY) Q3 2024 Earnings Call Transcript ↗

October 25, 2024

SNY earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent ↗

October 25, 2024

Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared.

Via Benzinga

Sanofi's Earnings Outlook ↗

October 24, 2024

Via Benzinga

NASDAQ:SNY is probably undervalued for the fundamentals it is displaying. ↗

October 03, 2024

SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals.

Via Chartmill

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat ↗

October 25, 2024

The company also hiked its profit outlook for the year and expects single-digit growth.

Via Investor's Business Daily

Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast ↗

October 25, 2024

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat estimates, reaching €13.44 billion, up 12.3%.

Via Benzinga

Markets Mixed Again; DECK, SKX Beat After The Bell ↗

October 25, 2024

Over the past week or so of trading, we’ve seen the stock market begin to snarl at current valuation levels.

Via Talk Markets

Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business ↗

October 21, 2024

Sanofi and private equity firm CD&R are in negotiations to sell a 50% stake in Opella, Sanofi's consumer healthcare division. With a €16B valuation, Opella is the third-largest player in the global OTC...

Via Benzinga

This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip? ↗

October 21, 2024

Let's look beyond this piece of bad news from regulators.

Via The Motley Fool

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer ↗

October 18, 2024

Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European...

Via Benzinga

France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block ↗

October 18, 2024

Sanofi is in talks with CD&R to sell a 50% stake in its consumer healthcare unit, Opella. PAI Partners raised its bid by 200 million euros as the French government weighs the sale due to national...

Via Benzinga

Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R ↗

October 15, 2024

France considers blocking Sanofi's $16 billion consumer division sale to U.S. firm CD&R, citing concerns over healthcare sovereignty, job protection, and local production amidst growing political...

Via Benzinga

World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice ↗

October 11, 2024

Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on...

Via Benzinga

Denali Therapeutics Stock Is Sliding After The Bell: Here's Why ↗

October 10, 2024

Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.

Via Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 07, 2024

Via Benzinga

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains ↗

October 07, 2024

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.

Via The Motley Fool

Topics Artificial Intelligence

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report ↗

October 04, 2024

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...

Via Benzinga

Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati ↗

October 04, 2024

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes milestone payments and is expected to close by the end of 2024.

Via Benzinga

Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses ↗

October 04, 2024

Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization...

Via Benzinga

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next ↗

October 01, 2024

HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...

Via Benzinga

Topics Economy

Week In Review: Zenas Raises $259 Million In IPO ↗

September 28, 2024

It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259...

Via Talk Markets

Topics Initial Public Offering

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease ↗

September 27, 2024

The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3...

Via Benzinga

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent ↗

September 27, 2024

The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.

Via Investor's Business Daily

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

September 27, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

September 27, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs ↗

September 25, 2024

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...

Via Benzinga

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗

September 25, 2024

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.